New combo attack on lung cancer: drug plus local therapy may delay progression

NCT ID NCT07379476

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a local treatment (like radiation or ablation) to the standard drug osimertinib can better control advanced EGFR-mutated lung cancer. About 64 adults with stable disease after 3-6 months on osimertinib and up to 3 remaining active spots will be randomly assigned to continue the drug alone or add local therapy. The goal is to see if the combination improves the chance of staying progression-free at 18 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NSCLC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact